Press Release

Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union Apr 18, 2025 15:52 JST Eisai Co., Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union (EU). More info..

Eisai to Divest Rights for Pariet in China to Peak Pharma Apr 01, 2025 12:15 JST Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd., a CBC Group-controlled company. More info..

World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
Mar 25, 2025 16:28 JST

Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early Alzheimer's disease (early AD ) has received the Prime Minister's Award at the 12th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES).
More info..

Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace Mar 25, 2025 11:21 JST Eisai Co., Ltd. announced today that it has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Nadeshiko Brand 2025 as a listed company excelling in the promotion of women in the workplace. More info..

Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 10, 2025 19:24 JST

Eisai Co., Ltd. announced today that it has been recognized as the 2025 KENKO Investment for Health by Japan's Ministry of Economy, Trade, and Industry (METI) and the Tokyo Stock Exchange, for the first time as a company strategically carrying out efforts with regard to its employees' health from a management perspective.
More info..

Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 05, 2025 08:09 JST

Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. announced today that they will conclude their co-promotion based on the co-promotion agreement in Japan regarding the orally-administered antifungal agent NAILIN Capsules 100 mg (generic name: fosravuconazole) which is manufactured and marketed by Sato Pharmaceutical, as of March 31, 2025.
More info..

Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 04, 2025 16:22 JST

Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial decision to decline the approval of humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia).
More info..

"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell" Mar 03, 2025 14:41 JST Eisai Co., Ltd. announced today the launch of the new nutritional drink "Chocola BB Nightwell" (designated quasi-drug product), a nutritional drink to help recovery from the accumulated fatigue of the day during sleep, on Monday, March 3. More info..

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Mar 03, 2025 12:53 JST

Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Abeta; monoclonal antibody lecanemab, adopted in November 2024.
More info..

Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 20, 2025 12:29 JST

Eisai Co., Ltd. announced today that it has been selected for "Human CapitalLeaders 2024" and "Human Capital Management Gold Quality" in the "Human Capital Survey 2024" jointly conducted by HR Technology Consortium, HR Research Institute (ProFuture Inc.), MS&AD InterRisk Research & Consulting, Inc. and Association to Confirm the Human Investment Value for Enterprise.
More info..

Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 14, 2025 11:09 JST

Oita University and Eisai Co., Ltd. announced today the development of a machine learning model to predict amyloid beta (Abeta) accumulation in the brain, combining background data such as age, gender, smoking history and medical history, as well as general blood test and MMSE items.
More info..

Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Feb 03, 2025 16:23 JST

National Center for Geriatrics and Gerontology and Eisai Co., Ltd. announced today that Eisai has created the "Guidance on Reducing the Risk of Cognitive Decline and Nutrition" and the "Handbook for Developing Home Delivery Meals/Meal Kits that Contribute to Reducing the Risk of Cognitive Decline" under the supervision of NCGG.
More info..

FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 28, 2025 08:46 JST

Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the Supplemental Biologics License Application (sBLA) for once every four weeks lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing.
More info..

Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company Jan 22, 2025 16:18 JST Eisai Co., Ltd. announced today that it has been listed in the 2025 Global 100 Most Sustainable Corporations in the World (Global 100), a global ranking by Canada-based media and investment advisory company, Corporate Knights, Inc. More info..

FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 15, 2025 09:03 JST

Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Biologics License Application (BLA) for lecanemab-irmb (U.S. brand name: LEQEMBI) subcutaneous autoinjector (SC-AI) for weekly maintenance dosing.
More info..

Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
Jan 07, 2025 08:14 JST

A collaborative research group led by Professor Kenjiro Ono of the Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, and Eisai Co., Ltd.
More info..

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 23, 2024 16:22 JST

Fujirebio Holdings, Inc., a wholly-owned subsidiary of H.U. Group Holdings, Inc., and Eisai Co., Ltd. announced today that they have entered into a memorandum of understanding for the joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases.
More info..

Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia Dec 11, 2024 13:45 JST Eisai Co., Ltd. announced today that it has received approval for "URECE(R)" (generic name: dotinurad) from the National Medical Products Administration in China as a treatment for gout patients with hyperuricemia. More info..

"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Dec 05, 2024 10:22 JST

Eisai Co., Ltd. and Biogen Inc. announced today that the Federal Commission forthe Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early Alzheimer's disease (AD).
More info..

LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Nov 28, 2024 15:26 JST

Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" has been launched in South Korea. LEQEMBI received the Ministry of Food and Drug Safety (MFDS) approval in May 2024 for treatment in adult patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia (early AD).
More info..

Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan Nov 26, 2024 14:50 JST The research will be implemented by the Japan Agency forMedical Research and Development (AMED), with NCNP as the lead research institution. More info..

Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 10:51 JST

Eisai Co., Ltd. announced today that the amyotrophic lateral sclerosis (ALS) treatment "Rozebalamin for Injection25 mg" (mecobalamin) has been launched in Japan as a treatment for slowing progression of functionalimpairment in amyotrophic lateral sclerosis.
More info..

Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 09:24 JST

Eisai Co., Ltd. announced today that it has launched fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor "TASFYGO Tablets 35mg" (generic name: tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy.
More info..

Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 16:33 JST

Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be broadcast nationwide in Japan from November 15 with the aim of increasing public understanding of MCI (Mild Cognitive Impairment).
More info..

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 15, 2024 13:31 JST

Eisai Co., Ltd. and Biogen Inc. announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab.
More info..

Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 05, 2024 10:35 JST

Eisai Co., Ltd. and Eisai's corporate venture capital subsidiary, Eisai Innovation, Inc. announced today that Eisai Innovation,Inc. has been selected as a registered venture capital (Registered VC) of the Strengthening Program for Pharmaceutical Startup Ecosystem implemented by the Japan Agency for Medical Research and Development (AMED).
More info..

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Nov 01, 2024 12:56 JST

Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
More info..

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 12:56 JST

Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Clinical Trials for Alzheimer's Disease Conference (CTAD), held in Madrid, Spain, and virtually.
More info..